Effects of Expanding Envelope Fluctuations on Consonant Perception in Hearing-Impaired Listeners

This study examined the perceptual consequences of three speech enhancement schemes based on multiband nonlinear expansion of temporal envelope fluctuations between 10 and 20 Hz: (a) “idealized” envelope expansion of the speech before the addition of stationary background noise, (b) envelope expansion of the noisy speech, and (c) envelope expansion of only those time-frequency segments of the noisy speech that exhibited signal-to-noise ratios (SNRs) above −10 dB. Linear processing was considered as a reference condition. The performance was evaluated by measuring consonant recognition and consonant confusions in normal-hearing and hearing-impaired listeners using consonant-vowel nonsense syllables presented in background noise. Envelope expansion of the noisy speech showed no significant effect on the overall consonant recognition performance relative to linear processing. In contrast, SNR-based envelope expansion of the noisy speech improved the overall consonant recognition performance equivalent to a 1- to 2-dB improvement in SNR, mainly by improving the recognition of some of the stop consonants. The effect of the SNR-based envelope expansion was similar to the effect of envelope-expanding the clean speech before the addition of noise

Thromboelastography results on citrated whole blood from clinically healthy cats depend on modes of activation

<p>Abstract</p> <p>Background</p> <p>During the last decade, thromboelastography (TEG) has gained increasing acceptance as a diagnostic test in veterinary medicine for evaluation of haemostasis in dogs, however the use of TEG in cats has to date only been described in one previous study and a few abstracts. The objective of the present study was to evaluate and compare three different TEG assays in healthy cats, in order to establish which assay may be best suited for TEG analyses in cats.</p> <p>Methods</p> <p>90 TEG analyses were performed on citrated whole blood samples from 15 clinically healthy cats using assays without activator (native) or with human recombinant tissue factor (TF) or kaolin as activators. Results for reaction time (R), clotting time (K), angle (α), maximum amplitude (MA) and clot lysis (LY30; LY60) were recorded.</p> <p>Results</p> <p>Coefficients of variation (CVs) were highest in the native assay and comparable in TF and kaolin activated assays. Significant differences were observed between native and kaolin assays for all measured parameters, between kaolin and TF for all measured parameters except LY60 and between native and TF assays for R and K.</p> <p>Conclusion</p> <p>The results indicate that TEG is a reproducible method for evaluation of haemostasis in clinically healthy cats. However, the three assays cannot be used interchangeably and the kaolin- and TF activated assays have the lowest analytical variation indicating that using an activator may be superior for performing TEG in cats.</p

Multicenter in vitro thromboelastography and thromboelastometry standardization

OBJECTIVE: To establish and compare the repeatability and reproducibility of activated thromboelastography (TEG) and thromboelastometry (ROTEM) assays. DESIGN: Multicenter in vitro test standardization. SETTING: Veterinary academic centers. ANIMALS: Test samples were obtained from normal, healthy dogs. Sixty identical 5 mL aliquots of canine platelet-rich plasma collected by apheresis, frozen in 6% dimethyl sulfoxide, were tested initially. Sixty identical 6 mL aliquots of canine fresh frozen plasma with admixed cryoprecipitate were subsequently evaluated. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Frozen study samples, quality controls, reagents, and consumables were distributed to participating centers (7 TEG and 3 ROTEM). TEG centers analyzed study samples with kaolin and tissue factor activated assays; ROTEM centers ran proprietary ellagic acid activated and tissue factor activated assays. All machines underwent quality control prior to sample analysis. Within- and between-center coefficients of variation (CVs) were calculated and compared using Mann-Whitney tests and calculation of intraclass correlation coefficients. Within and between centers, individual parameters for both TEG and ROTEM assays were comparable. Both within-center and between-center CVs varied markedly (0.7-120.5% and 1.4-116.5%, respectively) with assay type, instrument, and parameter. CVs for equivalent parameters were not significantly different between the 2 platforms. Intraclass correlation coefficients suggested moderate agreement between centers. In general, individual parameter CVs for platelet-rich plasma samples were lower in TEG centers, while CVs for canine fresh frozen plasma with admixed cryoprecipitate samples were lower in ROTEM centers. CONCLUSIONS: More variation within and between centers was identified than anticipated, but some parameters such as alpha angle were repeatable and reproducible. Sample types for future multicenter standardization efforts will require further optimization and may need to be adapted separately to each platform. Individual centers using viscoelastic tests for evaluation and management of clinical patients should take steps to minimize preanalytical and analytical sources of variation

Evaluation of the TEG(® )platelet mapping™ assay in blood donors

BACKGROUND: Monitoring of antiplatelet therapy in patients at cardiovascular risk is difficult because existing platelet function tests are too sophisticated for clinical routine. The whole blood TEG(® )Platelet Mapping™ assay measures clot strength as maximal amplitude (MA) and enables for quantification of platelet function, including the contribution of the adenosine diphosphate (ADP) and thromboxane A2 (TxA2) receptors to clot formation. METHODS: In 43 healthy blood donors, the analytical (CV(a)) and inter-individual variability (CV(g)) of the TEG(® )Platelet Mapping™ assay were determined together with platelet receptor inhibition in response to arachidonic acid (AA) and ADP. RESULTS: The CV(a )of the assay for maximal platelet contribution to clot strength (MA(Thrombin)) was 3.5%, for the fibrin contribution to clot strength (MA(Fibrin)) 5.2%, for MA(AA )4.5% and for MA(ADP )it was 6.6%. The MA(Thrombin )CV(g )was 2.8%, MA(Fibrin )4.7%, MA(AA )6.6% and for MA(ADP )it was 26.2%. Females had a higher MA(Thrombin )compared to males (62.8 vs. 58.4 mm, p = 0.005). The platelet TxA2 receptor inhibition was 1.2% (range 0–10%) and lower than for the ADP receptor (18.6% (0–58%); p < 0.0001). CONCLUSION: The high variability in ADP receptor inhibition may explain both the differences in response to ADP receptor inhibitor therapy and why major bleeding sometimes develops during surgery in patients not treated with ADP receptor inhibitors. An analytical variation of ~5 % for the TEG(® )enables, however, for routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy